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PREFACE 
 
 
This study was realized in the Molecular Oncology & Viral Pathology Group of 
the Portuguese Oncology Institute of Porto (IPO Porto).  
A systematic review of literature is being prepared to be published: Ribeiro J, 
Oliveira C, Sousa H. EBV LATENCY PATTERN IN GASTRIC CARCINOMAS: A 
SYSTEMATIC REVIEW.  
The results obtained in this study are being prepared to be included in different 
publications to be submitted in the near future. 
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RESUMO 
O EBV é um vírus associado a cancro que infecta cerca de 90% da população 
mundial, sem causar sintomas na maioria dos portadores ao longo da vida. A infeção por 
EBV pode adotar quatro diferentes padrões de latência, a latência 0, I, II, e III, que parecem 
estar correlacionados com os diferentes tipos de doenças associadas ao EBV. . No entanto, 
há algumas dúvidas sobre a expressão de genes latentes do EBV em diferentes doenças 
tais como o carcinoma nasofaríngeo e o carcinoma gástrico. 
Foi realizado um estudo retrospetivo com 23 casos de carcinoma da nasofaringe e 
9 casos de carcinoma gástrico associados ao EBV, a fim de avaliar a expressão de 
proteínas do EBV nos diferentes tumores e tentar estabelecer uma correlação clínica entre 
a latência viral e a malignidade. A deteção do EBV foi feita por EBER-IHS e a deteção de 
proteínas do EBV (LMP1 e LMP2a) foi realizada por imuno-histoquímica. Todos os casos 
utilizados neste estudo foram EBV positivos. 
LMP1 esteve presente em 95,5% dos casos de carcinoma da nasofaringe, mas 
nenhum dos casos de carcinoma gástrico mostrou ter expressão LMP1. Em relação á 
LMP2a, ela foi expressa em 100% dos casos de carcinoma da nasofaringe, enquanto no 
carcinoma gástrico estava presente em 44,4%. A expressão proteica de cada um dos 
tumores levou a diferentes tipos de latência. No carcinoma da nasofaringe, 21 casos 
(95,5%), apresentaram expressão de LMP1 e LMP2a, o que corresponde a um padrão de 
latência II, e apenas 1 caso (4,5%) expressou um padrão de latência distinto semelhante à 
latência II, mas sem a expressão de LMP1. No carcinoma gástrico, 5 casos (55,5%) não 
apresentavam expressão de LMP1 e LMP2a, que corresponde a um padrão de latência I. 
Os restantes 4 casos, tiveram o mesmo padrão de latência que um caso de carcinoma da 
nasofaringe onde há expressão de LMP2a, mas não de LMP1. Esses dados confirmam os 
padrões de latência associados ao carcinoma da nasofaringe (latência II) e com o 
carcinoma gástrico (latência I). Identificou-se também um padrão de latência novo e ainda 
não aceite  (latency II-like) que é especialmente importante no carcinoma gástrico, e é 
caracterizado por a expressão de EBNA 1 e LMP2a. 
Este foi o primeiro estudo realizado em Portugal para caracterizar os padrões de 
latência do EBV em diferentes neoplasias. Em conclusão, mesmo com a confirmação que 
o carcinoma da nasofaringe expressa tipicamente um padrão Latência II e o carcinoma 
gástrico a latência I, observou-se também que alguns casos expressam um perfil de 
latência diferente. Portanto, há uma necessidade de uma determinação correta da 
expressão de proteínas do EBV para um conhecimento correto sobre os mecanismos de 
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transformação. A literatura suporta a necessidade de reestruturação dos padrões de 
latência, considerando a expressão de todos os tipos de expressão de proteínas. 
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ABSTRACT 
 
EBV is a human cancer-associated virus that infects about 90% of the global 
population, without causing major symptoms in the majority of lifelong carriers trough the 
establishment of a viral latent state. EBV infection can adopt four different patterns of 
latency, named type 0, I, II, and III, which seem to be correlated with the different types of 
EBV associated disease. Nevertheless, there is some doubt on the differential expression 
of EBV latent genes in different diseases such as Nasopharyngeal Carcinoma and Gastric 
Carcinoma.  
We have performed a retrospective study with 23 NPC and 9 EBVaGC cases, in 
order to evaluate the expression of EBV proteins in different tumors and try to establish a 
clinical correlation between the viral latency and the malignances. The identification of EBV 
was made by EBER-ISH and the detection of EBV proteins (LMP1 and LMP2a) was 
performed by immunohistochemistry. All cases used in this study were EBV positive 
LMP1 was present in 95.5% of NPC cases, but in none EBVaGC was shown LMP1 
expression. Regarding the LMP2a, it was expressed in 100% of NPC cases, while in GC it 
was present in 44.4%. The protein expression that each of the tumour presented led to 
different latency types. In NPC, 21 cases (95.5%), had the expression of both LMP1 and 
LMP2a, which corresponds to a latency II pattern, and only 1 case (4.5%) expressed a 
distinct latency pattern similar to latency II, but without the expression of LMP1. In GC, 5 
cases (55.5%) had no expression of LMP1 and LMP2a, wich corresponds to a latency I 
pattern. The remaining 4 cases, had the same latency pattern as one case of NPC were 
there is expression of LMP2a, but not LMP1. These data confirm the latency patterns 
associated with NPC (latency II) and with EBVaGC (latency I).  We also identified a novel 
and yet not accepted latency (latency II-like) that is especially important in EBVaGC, 
characterized by the expression of EBNA1 and LMP2a.   
This was the first study in Portugal to characterize the latency patterns of EBV in 
different diseases. In conclusion, even with the confirmation of NPC as typically expressing 
a Latency II pattern and EBVaGC a latency I, we observed that some cases express a 
different latency profile. Hence, there is an urge in the correct determination of EBV profile 
expression for a correct knowledge on the mechanisms of transformation. The literature 
supports the need for restructuring the latency patterns, considering the expression of all 
types of protein expression. 
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ABREVIATIONS LIST 
 
BARTs - BamHI A rightward transcripts 
B-CLL - B-Chronic Lymphocytic Leukemia  
BL- Burkitt’s Lymphoma 
CSF - colony stimulating factor 
EBNAs - Epstein Barr Nuclear Antigens 
EBERs - Epstein-Barr Virus-encoded RNAs 
eBL - Endemic BL 
EBV - Epstein-Barr virus 
EBVaGC - Epstein-Barr virus associated gastric carcinoma 
GC - gastric cancer 
gH - glycoprotein H 
GIST - gastrointestinal stromal tumours  
gM - glycoprotein M 
gN - glycoprotein N 
HHV4 - Human Herpesvirus 4 
HIV - human immunodeficiency vírus  
HL - Hodgkin lymphoma  
HSV - herpes simplex virus 
IHC - immunohistochemistry 
IM - Infectious mononucleosis 
IRs - internal repeat sequences 
Kb - kilobase pairs 
LELC - lymphoepithelioma-like gastric carcinomas 
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LMPs - Latent Membrane Proteins 
LPHL - lymphocyte-predominant 
M-CSF - macrophage colony-stimulating factor 
MHC - Major histocompatibility complex 
miR-BARTs – EBV microRNAs 
miRNAs - microRNAs 
NET - neuroendocrine tumours 
NPC - nasopharyngeal carcinoma 
ori-lyt - lytic origin of replication 
PML - Promyelocytic Leukemia gene 
PTLD - Post-transplant lymphoproliferative disease  
sBL - Sporadic Burkitt’s lymphoma 
STAT1 - activation of transcription 1 
TF - transcription factor 
TLR3 - Toll-like receptor 3 
TRs - terminal direct repeats 
VCA - viral capsid antigen 
WHO - World Health Organization  
ZEBRA - Z Epstein–Barr replication activator 
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1. Epstein-Barr Virus 
 
1.1. Historical Background 
In 1958, Denis Burkitt identified a frequent cancer among children in Equatorial 
Africa [1, 2]. This tumour was dependent on climatic and geographical conditions, which led 
to the possibility that it could be associated with a vector-borne agent [1]. Later, in 1964, 
Anthony Epstein, Yvonne Barr and Bert Achong using electronic microscopy discovered 
typical herpesvirus particles in biopsies of the named Burkitt’s Lymphoma (BL), which they 
have called Epstein-Barr Virus (EBV). In the late 1960s, studies revealed that BL patients 
had higher antibody titers to EBV antigens [3, 4] These serological assays also allowed the 
identification of EBV as the etiological agent of infectious mononucleosis (IM) and 
nasopharyngeal carcinoma (NPC) [5, 6].  
 
1.2. EBV Structure and Genome  
EBV also recognized as Human Herpesvirus 4 (HHV4), belongs to the Herpesviridae 
family, Gammaherpesvirinae subfamily and is the only human virus from the 
Lymphocryptovirus genus [7]. The virion of EBV is about 120-300 nm in diameter and 
consists of a toroid shaped protein core wrapped with linear double stranded DNA with 
approximately 172 kilobase pairs (kb) in an icosahedral nucleocapsid with 162 capsomeres, 
an outer envelope with external glycoprotein spikes and a tegument protein between the 
nucleocapsid and envelope (Figure 1) [8-11].  
 
Figure 1: EBV virion structure (adapted from http://viralzone.expasy.org/viralzone/all_by_species/185.html) 
EBV genome has several terminal repeats (TRs) and internal repeat sequences (IRs) 
that divide the genome into short and long unique sequence domains (Figure 2) [12]. The 
EBV genome is linear, but once it reaches the nucleus of the infected cell, it adopts an 
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episomal structure through the binding of the TRs, which is required for replication of the 
viral genome [13]. 
Only a very small fraction of the EBV genome that enters the cell is able to reach the 
nucleus and an even smaller fraction is able to circularize. During cellular proliferation, linear 
viral genomes are gradually lost while circular DNA is maintained [14, 15] Indeed, during 
latency, EBV DNA acts like the celular DNA, being associated with histones and replicating 
once during the S phase, depending only on the cellular machinery and being equally 
transmitted to daughter cells [13]. 
By gene sequencing of different EBV isolates it was possible to identify two different 
EBV subtypes, which were classified as type 1 and type 2 (or type A and type B, 
respectively) [16]. The difference between these two subtypes are mainly on genetic 
polymorphism in the Epstein Barr Nuclear Antigens (EBNAs), but other single base changes 
may be observed in other regions of the genome [9, 17-19]. Type 1 is observed in almost 
all populations, being predominant in Europe, America, South America and Asia; while type 
2 is mainly found in Central Africa, New Guinea and in Alaskan Eskimos [20]. The influence 
of these EBV subtypes in disease development is not yet understood, but type 1 virus 
seems to prevail in most EBV positive associated diseases, whereas type 2 is mainly 
associated with immunocompromised patients [21]. 
 
 
 
 
 
Figure 2: Map of EBV genome (Straus, 1993)  
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1.3. EBV Infection  
EBV infection is restricted to humans, and is transmitted almost exclusively by saliva 
[5]. The primary infection usually occurs early in life and the family is frequently responsible 
for the transmission, although in developed countries this infection can be delayed until 
adolescence or adulthood and here it can lead to the development of a strong immune 
response medically known as IM [5, 22, 23]. After controlled, the infection is asymptomatic 
due to the establishment of a viral latency within the memory B lymphocytes [24]. In fact, 
EBV establishes a persistent lifelong infection, in most cases without consequences, in 
more than 90% of the world population [25, 26].  
It is assumed that the primary infection occurs in the oropharynx, due to the interaction 
of the viral membrane glycoprotein gp85/42, with a Major histocompatibility complex (MHC) 
class II receptor on the surface of lymphoepithelial cells of the Waldeyer's ring [27]. 
Subsequently, EBV starts a short period of lytic replication, after which it is released into the 
saliva and infects adjacent epithelial cells (Figure 3) [27]. 
 
Figure 3: Interactions between Epstein–Barr virus and host cells (Young, 2004) 
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Then, after the infection of epithelial cells in the oropharynx, EBV infects immature B 
lymphocytes that are nearby, process only possible due to the binding of EVB's membrane 
glycoprotein gp350 / 220 with the CD21 molecule of B lymphocytes [28]. The infected B-
lymphocytes will be transformed into lymphoblastoid cells with latent EBV, proliferating 
without control. Many of these proliferating cells are killed by cytotoxic T-lymphocyte 
response, nevertheless some escape through downregulation of antigen expression and 
the establishment of a stable reservoir of memory B lymphocytes where viral antigen 
expression is almost nonexistent [29]. 
 
1.4. Viral gene expression 
As all other herpesviruses, EBV has a life cycle with different viral gene expression 
programs: a latent one, on which no viral particles are formed; and a lytic one, on which 
new infectious viruses are produced [16]. There are more than 90 viral proteins coded by 
the EBV genome and the great majority has no known function [30].  
 
1.4.1. Lytic genes 
EBV establishes a latent persistent lifelong infection in most cases, nevertheless, for 
reasons not yet understood, the virus can reactivate and restart its lytic cycle in specific 
conditions [24]. By analogy with other herpesviruses, the proteins expressed in this phase 
are classified as immediate-early, early, and late lytic proteins: Immediate-early genes are 
transcribed after infection in the presence of protein synthesis inhibitors; Early genes are 
expressed in the presence of viral DNA synthesis inhibitors; and late genes are not 
transcribed when these inhibitors are present.  
EBV lytic genes are named by BamHI fragment within which they are located, whether 
they are expressed in a leftward (L) or rightward direction (R), and the number of their 
position in the BamHI fragment. For example, BZLF1 is the first transcript expressed in the 
leftward direction in the BamHI Z fragment of EBV (Figure 4) [31]. 
 
1.4.1.1. Immediate-Early Lytic Proteins 
Immediate-early genes are important for regulating gene expression in the virus. 
The major immediate-early proteins of EBV are encoded by BZLF1 and BRLF1, also named 
by Z Epstein–Barr replication activator (ZEBRA) or Zta and Rta, respectively.  BZLF1 and 
BRLF1 proteins activate transcription of viral early genes [32, 33]. BZLF1 protein inhibits 
transcription from the EBNA Cp promoter and may facilitate the switch from latent to lytic 
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infection [34]. BZLF1 protein also downregulates the interferon gamma receptor and inhibits 
the ability of interferon gamma to activate its target genes including IRF-1, CIITA, and MHC 
class II [31]. 
 
 
Figure 4: EBV lytic cycle activation 
 
1.4.1.2. Early Lytic Proteins 
EBV early lytic proteins include enzymes that are important for viral DNA replication, 
inhibition of apoptosis, and activation of gene expression. Six viral proteins have been 
identified as replication proteins originated by the lytic origin of replication (ori-lyt) [35]. 
These replication proteins are the viral DNA polymerase, encoded by BALF5, the DNA 
polymerase processivity factor, encoded by BMRF1, the single-stranded DNA-binding 
protein homolog, encoded by BALF2, the primase homolog, encoded by BSLF1, the 
helicase homolog, encoded by BBLF4, and the helicase-primase homolog, encoded by 
BBLF2/3. The viral thymidine kinase, encoded by BXLF1, phosphorylates acyclovir and 
results in activation of the drug with inhibition of the viral DNA polymerase and viral DNA 
replication0 [35]. Other early viral proteins important for viral DNA replication are the 
ribonucleotide reductase proteins encoded by BORF2 and BARF1 and the uracil DNA 
glycosylase encoded by BKRF3 [35]. 
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1.4.1.3. Late Lytic Proteins 
Late genes encode structural proteins of the virion: glycoproteins, nucleocapsid 
proteins, and a viral cytokine [36]. Most of the viral capsid antigen (VCA) is comprised of 
the major nucleocapsid protein, which is encoded by BcLF1 [36]. 
EBV encodes several glycoproteins including gp350, gp110, gp85, gp42, and gp25 [37]. 
The gp350, encoded by BLLF1, is the major viral envelope protein and it is able to bind 
CD21 contributing to the virus entry into the host B-cells. Deletion of gp350 from the virus 
markedly reduces the infectivity of the virus, and therefore purified recombinant gp350 is 
being studied as a vaccine candidate [37]. EBV gp110, encoded by BALF4, is the homolog 
of herpes simplex virus (HSV) glycoprotein B, which is required for HSV entry into cells. The 
three remaining EBV glycoproteins, gp85, gp42, and gp25, form a trimolecular complex, 
which is responsible for virion penetration of the B-cell membrane  [38]. EBV gp85, encoded 
by BXLF2, is the homolog of HSV glycoprotein H (gH), which is essential for the fusion of 
the virus to B-cells and absorption to epithelial cells [39, 40]. EBV gp25, the product of 
BKRF2, acts as a viral chaperone to transport gp85 to the cell membrane [41], and gp42, 
encoded by BZLF2, binds to MHC class II molecules [42] and functions as a co-receptor for 
virus entry in B-cells [43]. EBV also encodes homologs of HSV glycoprotein N (gN), 
encoded by BLRF1, and glycoprotein M (gM), encoded by BBRF3, that are important for 
egress of virus from the cell [44]. 
BCRF1 protein, also termed viral IL-10, shares over 80% amino acid identity with human 
IL-10 [45]. This viral IL-10 inhibits interferon gamma secretion by peripheral blood 
mononuclear cells and release of IL-12 from macrophages protecting virus-infected cells 
from cytotoxic T-cells.  [46]. Viral IL-10 also stimulates growth of B-cells and inhibits the 
activity of dendritic cells [47, 48].  
 
1.4.2. Latent genes 
From all viral proteins coded by EBV genome, only a restricted group may be expressed 
in different combinations during latency. [49]. Therefore, latency results from a tight interplay 
between viral and host transcription factors, leading to the distinct use of three viral 
promoters (Cp, Wp and Qp) which regulate the transcription of different viral genes [50]. 
The viral genes expressed during latency include: six EBV Nuclear Antigens (EBNA1, 2, 
3A, 3B, 3C and LP); three Latent Membrane Proteins (LMP1, LMP2A. and LMP2B); two 
small nonpolyadenylated Epstein-Barr Virus-encoded RNAs (EBER1 and 2) and highly 
spliced BamHI A rightward transcripts (BARTs) (Figure 5) [13, 51, 52].  
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1.4.2.1 EBV-nuclear antigens 
EBNA1 
EBNA1 is the only nuclear EBV antigen expressed in both latent and lytic modes 
and it is essential for efficient EBV genome replication, persistence and transcription in 
dividing cells. [53, 54]. This protein is expressed in all virus-associated tumours [55, 56]. 
Literature have referred several functions to EBNA1, such as binding to viral DNA elements 
and cellular promoters, activation EBV viral Cp and Wp promoters, inhibition of Qp 
promoters, upregulation signal transducers and activation of transcription 1 (STAT1), 
downregulation of tumour growth factor-β signaling pathways, reduction of SMAD2, 
upregulation of CCL20 [57], inhibition the canonical NF-KB pathway, and enhancing activity 
of the AP-1 transcription factor (TF) [56-63]. 
EBNA1 contributes to the latent infection as it suppresses spontaneous lytic reactivation 
and induces a family of microRNAs (miRNAs), which in turn decrease the level of cellular 
protein Dicer, inhibiting reactivation of latent EBV [64, 65]. EBNA1 has also been recognized 
as inducing the loss of Promyelocytic Leukemia gene (PML) nuclear bodies, and decreased 
p53 activation and apoptosis in response to DNA damage in NPC and EBV-associated 
gastric cancer (EBVaGC) [66].  
 
E B N A 2   
EBNA2 exists in two allelic forms, which differ in the amino acid sequence of the 
central region of the molecule [67]. Interestingly, each EBV subtype has a different EBNA2 
allelic form. This may probably account for the differences observed in the growth transformation 
abilities of each EBV subtype.  [68]. 
EBNA2 expression results from the same pre-mRNA as EBNA-LP, after an 
alternative splicing. These two viral proteins are the first EBV proteins expressed during EBV 
infection and B cells transformation, nevertheless, only EBNA2 and LMP1 essential for.EBV-
induced immortalization [69, 70]. EBNA2 by itself is responsible for the expression of 
several proteins such as LMP1, LMP2A, LMP2B and also the ones arising from the EBNA's 
Cp promoter [71-74]. EBNA2 activation of gene expression does not occur though direct 
binding of EBNA2 to DNA, but rather through the interaction with the cellular CBF1 (RBP-
J11) protein complex. One important target of EBNA2 is the cellular oncogene c-Myc, this 
link may be relevant for EBV induced proliferation and immortalization of B lymphocytes 
[75]. 
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EBNA3 FAMILY 
There are three EBNA3 proteins, EBNA3A, EBNA3B, and EBNA3C. Studies have 
demonstrated that, in contrast with EBNA3B, EBNA3A and EBNA3C are required for B-cell 
transformation [76, 77]. The EBNA3 proteins are responsible for increased expression of 
both cellular and viral genes. EBNA3C increases the expression of CD21 and co-activates 
the LMP1 promoter in conjunction with EBNA2, it interacts with the human metastatic 
suppressor protein Nm23-HI and inhibits the ability of the latter to suppress the migration of 
BL cells [78]. EBNA3C has also been shown to mediate the degradation of the 
retinoblastoma protein (pRb), with the assistance of the SCFSKP2 complex, in transiently or 
stably transfected cells [79, 80]. On the other hand, EBNA3B seems to upregulate CD40 
and bcl-2 expression [81-83]. These funtions reforce the ability of EBNA3C family in the 
maintenance of EBV latency and transformation [81-83].  
 
EBNA-LP 
 
Even though the role of EBNA-LP in EBV-induced B-cell transformation is still uncertain, 
it is thought that it plays an important role in the establishment of B-cell immortalization, 
once mutant viruses lacking the unique carboxy-terminal domain, are much less efficient at 
immortalizing B cells than wild-type viruses [84, 85]. EBNALP coactivates EBNA2 
enhancing the expression of the major viral oncoprotein LMP1 [85, 86]. While EBNA-LP has 
been shown to bind to p53 and the retinoblastoma protein, it is unclear what significance 
these interactions have for the role of EBNALP in B-cell transformation [87, 88]. In addition, 
EBNA-LP binds to a number of other cellular proteins including heat shock protein 70, DNA 
protein kinase catalytic subunit, HA95 a nuclear protein that may be involved in mitosis, and 
in a and b tubulin [87, 89]. 
 In newly infected B cells, a range of EBNA-LP isoforms are expressed, but over time, 
the number of expressed isoforms decreases [85]. In addition, EBNA-LP localizes diffusely 
throughout the nucleus within the hours post-infection, but with time, it associates with PML 
nuclear bodies [90].  
 
1.4.2.1. Latent membrane proteins 
LMP1 
LMP1 develops a key role in the immortalization of B cells and is considered a major 
EBV oncoprotein [91, 92]. It is a membrane protein composed of six hydrophobic clusters 
forming three membrane spanning domains connected to a short N-terminal cytoplasmic 
domain and also to a long C-terminal cytoplasmic tail of 200 amino acids [93, 94]. It is 
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relatively highly expressed in most EBV associated tumours, but its expression is rare in 
EBV infected healthy individuals [18, 95]. 
Several studies have demonstrated the LMP1 is involved in proliferation, apoptosis, 
angiogenesis, invasion and modulation of immune response, leading to dysregulation of 
various cellular pathways in tumour cells, and also affecting the tumour microenvironment [95-
97]. Thus, LMP1 is highly regulated and presents various functions in different cellular 
processes [94, 95, 97, 98]. Although it is a latent protein, its transcription is also observed 
during lytic infection [99, 100]. 
 
L M P 2  
LMP2A and LMP2B are LMP2 isoforms transcribed from 2 different promoters and 
differing only in the first exon [101, 102]. Both LMP2A and LMP2B are membrane proteins  
responsible for the maintenance of EBV latency and pathogenicity [101, 103].  
LMP2A is known to regulate several signaling pathways, like proliferation and survival 
of B cells even in the absence of normal BCR [104, 105]. LMP2A has been shown to 
interfere with switch from latency into lytic EBV infection, either by blocking the activation of 
protein tyrosine kinases usually associated with BCR or by providing surrogate BCR 
receptor signaling [103]. Moreover, it has been shown that LMP2A expression increases 
the signaling capacity of LMP1 in epithelial cells. [106, 107]. 
Although the LMP2A isoform has been well studied, the LMP2B function in EBV infection 
has not been yet uncovered, mainly due to technical limitations associated with inability to 
produce antibodies against this protein [101, 103]. Nevertheless, some in vitro studies 
indicate a co-localization of this protein with LMP2A at the cellular membrane. It seems 
that LMP2B negatively negatively regulates the function of LMP2A in preventing the switch 
from latent to lytic EBV replication, , resulting in increased susceptibility to induction of lytic 
EBV infection through modulation of BCR and downstream signaling [103].  
 
1.4.3. Other transcripts  
BARTs   
BARTs, are a family of multispliced rightward transcripts from the BamH1 A region of 
the EBV genome [108]. It has been suggested that they may play a special role in epithelial 
malignances, once they are expressed at high levels in EBV-infected epithelial cancers, but 
not in EBV-transformed lymphocytes [109, 110]. 
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EBV encodes a number of microRNAs (miR-BARTs), that are transcribed from the same 
BART transcript [111]. These miR-BARTs are believed to play a key role in tumourigenesis 
by targeting multiple viral and cellular genes, and prevention of apoptosis is its major 
function in epithelial cancers. In addition miR-BARTs are able to protect EBV-infected 
malignant epithelial cells by weakening the host immune response. [108, 111].  
Three BART cluster-1 miRNAs, miR-BART1-5p, -16 and -17-5p, can affect the growth-
promoting and pro-apoptotic actions of LMP1 by downregulation of its expression [112]. 
miR-BART3, on the other hand,  targets a nuclear importer receptor, importin 7 (IPO7), for 
immune evasion [113]. Recently studies showed that miR-BART22 suppressed expression 
of LMP2A in order to protect NPC cells from immunological attack [114]. miR-BART3-5p 
promotes cellular growth by targeting the DICE1 tumour-suppressor gene and miR-BART9 
targets E-cadherin to enhance invasiveness and metastatic capacity in NPC cells [115, 
116]. Moreover, the miR-BARTs facilitate EBV latency by limiting the expression of multiple 
lytic genes like BZLF1, BRLF1 and BALF5 in infected epithelial cells [117, 118].  
 
 
BARF1 
BARF1, encoded in the BamH1 A region, is a homologue of CSF1R, and blocks CSF-1 
mediated signaling, a pathway of innate immunity [119]. It is considered a major viral 
oncogene in epithelial cells, and is highly expressed in NPC and EBV associated gastric 
carcinoma (EBVaGC) [120, 121]. 
BARF1 may drive carcinogenesis by transforming and mortalizingin epithelial cells, and 
enable cell survival, by upregulating anti-apoptotic Bcl-2 [122]. Also, secreted hexameric 
BARF1 inhibits macrophage colony-stimulating factor (M-CSF), manipulating this way 
myeloid cell growth and functions [123]. In B cells and lymphomas, BARF1 expression is 
restrained to the viral lytic replication cycle [123]. 
 
EBERs 
EBV encodes two small RNAs, EBER1 and EBER2, which are non-polyadenylated, 
noncoding and expressed abundantly in all forms of cells latently infected with EBV [124]. 
Despite its abundance and well characterized structure, the function and mechanism of 
action is poorly understood. EBERs are reported to be involved in several cellular activities 
such as inhibition of apoptosis, increase cell proliferation and induction of tumour formation 
[125-127].  Literature suggests also, that EBER-1, which is the most abundant and stable 
of the two [128, 129], is excreted from cells as an RNA-protein complex and is able to induce 
pro-inflammatory cytokines such as IL-12 via Toll-like receptor 3 (TLR3) [128-130]. 
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EBERs can be used as target molecules for the detection of EBV-infected cells and are 
considered a reliable marker of the presence of EBV. [131]. 
 
Figure 5: EBV latent genes target cancer hallmarks, adapted from (Tsao, 2015) 
 
1. EBV-Associated Malignancies  
EBV is currently associated with lymphoid and solid tissue malignancies in both 
immunocompetent and immunocompromised individuals. The presence of EBV infection in 
tumour cells and viral genes capable of usurping normal cellular growth control, suggest 
that EBV infection plays a causal role in the development of these associated malignancies 
[52]. 
 
2.1. Burkitt’s Lymphoma 
 BL was first described as sarcoma of the jaw, but soon it became evident that this was 
a distinct form of Non Hodgkin’s lymphoma [132]. The highest incidence and mortality rates 
of BL are seen in Eastern Africa, and it affects mainly children of male gender [132]. 
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There are several forms of BL according to its geographic distribution, incidence 
magnitude and risk factors (Table 1). BL is a B-cell lymphoma genetically characterized by 
a chromosomal translocation that results in deregulation of the c-MYC oncogene [133].  
 
Characteristics Endemic BL Sporadic BL HIV associated BL 
Epidemiology 
 
Equatorial 
Median age 7 yrs 
Associated with 
malaria/Climate 
Median age 30yrs 
Children (30%) 
Older adults (1%) 
Low Socio Economical Status 
HIV risk groups 
Median age 10-19 
yrs 
Clinical Presentation 
Facial skeleton (50%), 
Central Nervous System 
(33%), other organs 
Abdominal, ileo-coecal (80%) 
Bone marrow (20%) 
Other organs also affected 
Organ and nodal 
presentation 
Pathology/Morphology Germinal centre B-cell 
Chromosomal 
translocations 
Monomorphic medium sized B cells with basophilic cytoplasm and  
multiple mitotic figures  
EBV association 95-100% 30% 30-50% 
 
Endemic BL (eBL) is the disease originally described by Burkitt and 95% of the cases 
are found in equatorial Africa (Figure 6), characteristically affecting the facial skeleton in 
children between ages two to nine  [134]. Sporadic Burkitt’s lymphoma (sBL) is the form 
usually described outside the endemic region and accounts for 1–2% of adult lymphoma in 
Western Europe and America. It is morphologically similar to eBL but affects mainly 
abdominal viscera. sBL can be detected at any age and no specific co-factor has been 
described [134]. A third subtype of BL has been proposed based on its association with 
the human immunodeficiency virus (HIV) infection. Though well described in the developed 
world and known among HIV positive adults in Africa, the childhood form of the disease 
among HIV positive children has not been well characterized [132].  
 
 
Table 1: Overview of Burkitt’s lymphoma clinical variants. 
Figure 6: Map of Africa showing the 'lymphoma belt' in which eBL occurs at high incidence. 
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BL has a very close association with EBV, with approximately 95% of eBL showing the 
presence of the EBV genome in their tumour cells, while the other form are associated with 
EBV in 30-50% of all cases [135]. 
 EBV plays a role in the pathogenesis of BL by deregulation of c-MYC activity and clonal 
expansion, direct mutagenesis and immune inactivation. Indeed, EBV is known to transform 
resting B cells into latently infected lymphoblastoid cells [132]. The majority of BL’s, show 
EBV latency I pattern. This cells carry a wild-type EBV genome and express only EBNA1 
from the latent promoter Qp [136]. However, around 15% of endemic tumours, carry an 
EBNA2 gene-deleted genome and express EBNA1, -3A, -3B, and -3C from the Wp latent 
promoter [137].  
 
2.2. Hodgkin’s Lymphoma  
Hodgkin lymphoma (HL) was first discribed it in 1832 by Doctor Thomas Hodgkin. 
HL is rare type of cancer, being only diagnosed 66,000 new cases of Hodgkin lymphoma 
worldwide in 2012, accounting to 0.5% of total cancer cases.  HL has a global spread, being 
more common in Asia and Europe (Figure 7) [138] HL is characterized by the presence of 
malignant multinucleated Reed Sternberg cells in a background of reactive inflammatory 
cells [13].  HL exists in five forms: mixed-cellularity, nodular-sclerosis, lymphocyterich, 
lymphocyte-depleted and lymphocyte-predominant (LPHL) subtypes. LPHL is the only one 
not associated with EBV [13].   
HL presentation can be very different, since, it can appear in all lymphoid nodes in 
the body (Figure 8). The most common place for Hodgkin lymphoma is in the lymph nodes 
in the neck, and >50% of diagnosis are at stage I or II (Appendix II) [139].  
Figure 7: Hodgkin Lymphoma incidence worldwide, both sexes, all ages, Globocan 2012  
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Studies suggest that 40% of HL cases, are associated with EBV. In these EBV 
infection exhibits a type II form of latency, being limited to the EBERs, EBNA1, LMP1, LMP2, 
and BARTs [140]. 
 
2.3. Post-transplant lymphoproliferative disease 
Post-transplant lymphoproliferative disease (PTLD) is a well-recognized complication of 
both solid organ transplantation and allogeneic hematopoietic stem cell transplantation [13]. 
This terms is used to describe lymphoproliferations, that are not always monoclonal and 
whose morphologic features often differ from those of lymphomas [141].  
PTLD are the second most frequent neoplasia in transplant patients, and its incidence 
varies depending on the organ transplanted, and ranges from 0.5% in adult kidney or liver 
recipients to more than 10% in lung, intestinal recipients or pediatric transplant patients 
(table 2) [142]. 
 
Organ Recipient Age 1 year (%) 3 years (%) 5 years (%) >5 years (%) 
Kidney 
Adulta) 0.46 0.87 1.18 ND 
Pediatric a) 1.73 2.45 ND ND 
Liver 
Adult a) 1.1 3 4 4.7 
Pediatric a) ND ND 6 ND 
Heart 
Adult b) 0.67 ND 1.3 2.0 
Pediatric b) 1.7 ND 4.6 7.9 
Lung 
Adult b) 1.6 ND 2.1 5.6 
Pediatric b) 4.8 ND 11.1 10.3 
*ND- Not Described; a) ISHLT 2008; b) French PTLD registry 
Table 2: Reported incidence of PTLD by organ system and recipient age  
Figure 8: Hodgkin Lymphoma body locations, from cancer research UK 
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Literature suggest that EBV infection has a major pathogenic role in PTLDs, infecting 
60%-80% of PTLD patients, including 100% of early-onset PTLD patients [28]. Up to 2/3 of 
PTLD cases are associated with EBV infection of B cells, either because of reactivation of 
the virus or from primary EBV infection [13, 102]. Recipients who are EBV seronegative 
have a higher risk of developing EBV-induced lymphoma, particularly pediatric patients 
[143, 144]. Literature suggest that EBV infection has a major pathogenic role in PTLDs, 
infecting 60%-80% of PTLD patients, including 100% of early-onset PTLD patients [28]. 
In most cases of PTLD, tumour cells express the latency III pattern, with some cells 
undergoing lytic replication [145]. However, there is variability between individuals once 
latency type I and II patterns have also been detected in PTLD biopsies. In these cases 
additional genetic or epigenetic changes are probably required for tumour outgrowth [146, 
147]. 
 
2.4. Nasopharyngeal Carcinoma  
NPC is a rare type of head and neck cancer that affects the upper part of oropharynx, 
the nasopharynx (Figure 9) [139]. NPC has been reported in almost all parts of the world, 
however, most cases are found in South East Asia, Southern China, North Africa and in the 
Eskimo population of Alaska (Figure 10) [148-150]. In 2012 it was reported 87 000 new 
cases of NPC at a global level, corresponding to 0.6% of all cases of cancer [138]. Because 
the nasopharynx is a deep-seated structure and the nasal and aural symptoms are 
nonspecific, a large portion of patients with NPC are only diagnosed when the tumour has 
reached advanced stages, III and IV (Appendix II) [139]. 
 
 
 
Figure 9: Nasopharynx location from cancer research UK 
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Taking into account 2003 WHO classification NPC can be divided in three main 
types: keratinizing squamous cell carcinoma, non-keratinizing carcinoma, which can be 
divided diferentiated and undifferentiated, finally in basaloid squamous cell carcinoma 
respectively [151, 152]. NPC as several risk factors, such as EBV infection and classic head 
and neck aetiological factors including alcohol and tobacco [153].  
Even though here is no doubt that NPC has a definite association with EBV, it is still 
not clear the specific pathogenic mechanism by which EBV causes NPC. A gap in the 
explanation of the EBV pathogenesis in the tumour is the fact that mature nasopharyngeal 
cells are not usually infected with EBV, though tumours have been shown to be infected 
before transformation [154]. It has been shown that the immature epithelial cells carry CD21 
and can be infected by the virus. It is therefore postulated that EBV infects nasopharyngeal 
cells that have been stimulated by other environmental factors [155-157].  
It appears that latency gene expression in NPC is intermediate between what is seen 
in latency I and latency II. The expression of EBNA1 and the EBERs are present in all EBV-
positive NPC cases [158, 159].  It also appears that LMP2A can be detected in about 50% 
of NPC [160, 161]. In other hand, LMP1 is identified readily in only 35% of cases. LMP1 has 
been identified in all pre invasive lesions, suggesting that its expression is necessary in 
early lesions but may not be as essential in established carcinomas [162].  
 
 
 
 
 
Figure 10: Nasopharyngeal carcinoma incidence worldwide, both sexes, all ages, Globocan 2012 
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2.5. Gastric Carcinoma  
GC is the sixth most common malignancy in both sexes worldwide with 952.000  
new cases estimated in 2012, corresponding to 6.8% of all cases of cancer [138]. The 
incidence rates are almost twice higher in male (8.5%) than in female (4.8%) with about 
631.000 and 320.000 new cases per year, respectively [138]. More than 70% of total cases 
occur in developing regions like Eastern Asia, Eastern Europe and Latin America. In 
contrast, the lowest incidence rates are observed in United States, Australia and some 
North European countries (figure 11) [138]. 
 Adenocarcinomas are about 95% of all GC and the other cases include: Squamous 
cells cancers; lymphoma; gastrointestinal stromal tumours (GIST); and neuroendocrine 
tumours (NET).  Histologically, GC can be classified by two different classifications, World 
Health Organization (WHO) and Lauren (Table 3) [163, 164] 
 
Table 3: Comparison of Lauren’s and WHO classification systems [153,154] 
 
 
 
WHO (2010) Lauren (1965) 
Papillary adenocarcinoma 
Intestinal Type Tubular adenocarcinoma 
Mucinous adenocarcinoma 
Signet-ring cell carcinoma 
Diffuse Type 
Poorly cohesive carcinoma 
Mixed carcinoma Indeterminate 
Uncommon variants - 
Figure 11: Gastric cancer incidence worldwide, both sexes, all ages, Globocan 2012  
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Anatomically, GC is divided into proximal and distal tumours depending on their 
localization of stomach. Proximal tumours are found in cardia region whereas distal 
carcinomas are often located in the antrum/pyloric region (Figure 12). 
 
  
 Gastric carcinogenesis is a multistep process, where different factors are involved, 
including EBV [165].  EBV-positive GC is present in 10% of all GCs [166, 167]. EBV infection 
has been detected in different types of gastric cancer: gastric adenocarcinomas and 
lymphoepithelioma-like gastric carcinomas (LELC) [168]. LELC represents about 4% of all 
gastric carcinomas and more than approximately 80% of cases have EBV-infected cells 
[168]. Actually, scientific community is still debating the role of EBV infection on gastric 
carcinoma, and recent studies have suggested that EBVaGC is a distinct subgroup of 
gastric cancers with specific molecular features [169, 170]. The evidence for involvement 
of EBV in gastric carcinoma is based on the specific presence of viral gene products such 
as EBERs in tumour cells but not in the surrounding non-neoplastic epithelium [171], the 
presence of clonal EBV in tumour cells [172] and elevated EBV antibodies in prediagnostic 
sera of patients with EBV-associated gastric carcinoma [173]. 
EBVaGC has typically a latency I pattern in which only EBNA1, EBERs and BARTs 
are expressed. Even though, in some cases it can also express a small amount of LMP2A, 
while LMP1 is rarely expressed in EBVaGC. In these cases, the genes expressed do not 
correspond to any classification of latency patterns described in the literature [167]. 
 
 
 
Figure 12: Illustrative scheme of the stomach regions from cancer research UK 
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3. EBV Latency 
EBV infection can adopt mainly four different programs of latency, named type 0, I, II, 
and III latency (table 4) (Figure 13) [106]. The different latency programs adopted, are 
dependent on several cell-specific factors such as epigenetic events, which include DNA 
methylation, histone modifications and chromatin organization. EBV latency within B cells 
usually progresses from Latency III to Latency II to Latency I.  [174, 175]. Moreover, latency 
programs have also been shown to correlate with the type of EBV associated disease, and 
they impose different phenotypic and functional properties on the viral genome carrying B 
cell [176, 177].  
 
Table 4: EBV gene latency programmes 
Latency 
type 
Transcripts 
EBV-associated 
disease 
 EBERS EBNA1 EBNA2 
EBNA3 
FAMILY 
EBNALP LMP1 LMP2  
Latency 0 + - - - - - - 
Memory B cells in 
healthy individuals 
Latency I + + - - - - - 
Burkitt lymphoma, 
Gastric Carcinoma 
Latency II + + - - - + + 
Hodgkin lymphoma, 
Nasopharyngeal 
Carcinoma 
Latency III + + + + + + + 
Post-transplant 
lymphoproliferative 
disease 
 
3.1. Latency 0 
Although EBV-infected proliferating B cells are eliminated by cytotoxic T cells in vivo, 
the virus is not totally eliminated from the body. Instead, EBV is able to establish in vivo 
latency, called latency 0 in memory B cells [2]. The switch from proliferation to latency 0 in 
memory B cells is still poorly understood. In this type of latency no viral gene expression is 
found [178]. 
 
3.2. Latency I 
In type I latency only EBNA1 is expressed from the Qp promoter, while all the other 
latency-associated promoters remain silent [137]. Although the mechanism behind the 
switch in promoters is not completely understood, the repression of the Cp promoter during 
this period seems to be related to DNA methylation [174]. During type I latency, transcription 
of the viral transcripts EBERs and BARTs has also been described [30]. This type of latency 
is mainly associated with BL and GC.  
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3.3. Latency II 
Another main type of latency, type II, is characterized by the expression of the following 
viral genes: EBNA1, LMP1 and LMP2, EBERs and BARTs. This type of expression was 
first detected in NPC in epithelial cells [179]. This type of latency can also be found in EBV 
positive Reed/Sternberg cells of HL of B cell origin [140, 180]. 
 
3.4. Latency III 
Type latency III expresses all latent genes and can be found in PTLD. The EBV’s role 
in cell growth is most evident in latency III, as EBNA2, EBNALP, EBNA3A and EBNA3C 
coordinately upregulate cMyc expression and cell proliferation, and EBV LMP1 enhances 
cell survival [76, 84, 181-184].  
 
3.5. Other types of latency 
Additionally to these thoroughly studied three latency programs, other types of EBV latency 
have also been described such as, a pattern which is found in some gastric  and 
nasopharyngeal carcinomas in which EBNA1 and LMP2A are the only genes detected. This 
pattern is is described by the majority of authors as latency II-like, however, in some studies 
focused on only NPC  the denomination latency IIb is also found [167, 185-189]. In a group 
of BL tumours, another pattern of latent gene expression has been described in which the 
expression of EBNA1, -3A, -3B, -3C and truncated EBNALP is observed, but not the 
expression of EBNA2 or LMPs. Since this latency program was found to be associated with 
the exclusive transcription from the Wp promoter, it was therefore called "Wp-restricted 
latency"[137, 190].  Another type of latency named latency IIb which lacks LMP1 but 
expresses EBNA2, was first seen in B-Chronic Lymphocytic Leukemia (B-CLL) cells 
infected with EBV in vitro [191].  
 
 
 
 
 
 
 
 
Figure 13: EBV cycle and latent states (Thorley-Lawson, 2008) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II. AIMS OF THE STUDY 
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Although there are many studies in this field, it is still not clear the latency pattern 
present in several malignancies, especially in gastric carcinoma. Therefore, it is necessary 
to clarify and understand which EBV proteins are expressed, in order to serve as a starting 
point for carcinogenesis studies.  
The aim of this study is to characterize EBV latency in NPC and GC evaluating the 
expression of EBV proteins in different tumors’ and try to establish a clinical correlation 
between the viral latency and the malignances.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
III. MATERIAL AND 
METHODS
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1. Population and Type of study  
A retrospective cross-sectional study was performed using a total of 32 patients, with 
confirmed EBV-associated NPC and with EBVaGC attended at Portuguese Oncology 
Institute of Porto (IPO Porto).  
Inclusion criteria: patients with histological confirmation of EBV associated cancer with 
representative tumour blocks for adequate evaluation of EBV presence. All tumours were 
submitted to histological examination by an experimented pathologist from our institution 
and classified according to the guidelines for each type of cancer.  
This study did not interfere with the routine procedures. Clinicopathological data was 
collected from individual clinical records and inserted on a database with unique 
codification. All procedures were approved by the ethical committee of IPO Porto (CES IPO 
74/2015).  
 
 
The group of NPC cases, included 22 cases that were diagnosed between 2010 and 
2014, and it consisted of 16 males and 6 females with median age of 55 years old (Table 
5). 
 
 
 
 
 
 
 
 
Variable  
Gender  n(%) 
      Male 17 (73.9) 
      Female 6 (26.1) 
Age  
      Median 55 ± 14,7 
      Minimum 20 
      Maximum 77 
Histology (WHO 2003) n(%) 
      Undifferentiated non-keratinizing carcinoma         23 (100) 
Table 5: Characterization of Nasopharingeal carcinoma cases 
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The group of EBVaGC cases, included 9 cases that were diagnosed in 2011, and it 
consisted of 7 males and 2 females with median age of 69 years old (Table 6). 
 
 
 
 
2. Sample collection and processing  
Tumour tissues were collected from the institution archives and histological sections (3 
µm slides) were obtained from formalin-fixed paraffin-embedded (FFPE) tissue blocks.  
 
3. EBV detection (EBER-ISH) 
Tissue samples were dewaxed in xylene for 2 x 3 minutes. After dewaxing, slides were 
sequentially hydrated in 100% v/v ethanol for 2 x 3 minutes, 96% v/v ethanol for 3 minutes 
and distilled water for 2 x 3 minutes. Proteolytic treatment was performed by addition of 10 
Variable  
Gender  n(%) 
      Male 7 (77.8) 
      Female 2 (22.2) 
Age  
      Median 69 ± 10,994 
      Minimum 52 
      Maximum 82 
Surgical Procedure  n(%) 
      Subtotal Gastrectomy 2 (22.2) 
      Total Gastrectomy 7 (78.8) 
Histology  n(%) 
      WHO 2010  
      Mixed Adenocarcinoma 2 (22.2) 
      Tubular Adenocarcinoma 5 (55.6) 
      Carcinoma with lymphoid stroma         2 (22.2) 
      Lauren (1965)        
      Intestinal types         5 (55.6) 
      Indeterminate types         2 (22.2) 
      lymphoepithelioma-like carcinoma         2 (22.2) 
Invasion pattern  n(%) 
      Expansive  6 (33.3) 
      Infiltrative  3 (67.7) 
Table 6: Characterization of gastric carcinoma cases 
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mM proteinase K and incubation at 37ºC during 30 minutes. Finished the incubation time, 
endogenous peroxidase activity was blocked by incubating the slides in 3% hydrogen 
peroxide (H2O2) for 10 minutes at room temperature, then solution the slides were immersed 
in distilled water for 2 x 3 minutes and then dehydrated in 96% v/v ethanol followed 100% 
v/v ethanol for 3 minutes to facilitate air drying. 
Epstein-Barr virus was identified by in situ hybridization (ISH) for detection of EBV-
encoded small RNA (EBER). Hybridization results in duplex formation of sequence present 
in EBV infected cells (EBERs) and specific probe. The BondTM Ready-to-use ISH EBER 
Probe (Leica, Newcastle upon Tyne, UK) was used with a volume of 20 µl for each slide. 
Slides were covered with coverslip, and then incubated at 37ºC for 2 hours.  Nonspecific 
antibody binding was block using UltraVision Large Volume Detection System Anti-
Polyvalent, HRP (THERMO SCIENTIFIC, Fremont, USA). It was incubated for 10 minutes 
at room temperature and washing was performed with TBS, 0.1% v/v Trinton X-100 (TBS-
T) 2x 5 minutes. 
EBERs detection was performed with BondTM Anti-Fluorescein Antibody (Leica, 
Newcastle upon Tyne, UK) diluted 1:150 in TBS, 3% m/v BSA, 0.1% v/v Trinton X-100 with 
incubation at room temperature for 30 minutes. After washing 2 x 3 minutes with TBS, the 
revelation of hybrids was performed with the UltraVision Large Volume Detection System 
Anti-Polyvalent, HRP (THERMO SCIENTIFIC, Fremont, USA). Briefly, the Biotinylated Goat 
Anti-Polyvalent Antibody (THERMO SCIENTIFIC, Fremont, USA) was added at room 
temperature for 10 minutes, washed with TBS-T 2 x 5 minutes followed by the addition of 
Streptavidin Peroxidase (THERMO SCIENTIFIC, Fremont, USA) with incubation for 10 
minutes at room temperature. Streptavidin shows high affinity with several secondary 
antibody-conjugated biotin molecules providing a good revelation signal. Detection of 
hybrids is achieved by enzymatic reaction using a specific substrate to peroxidase. 
ImmPACTTM DAB, Peroxidase Substrate (VECTOR, Burlingame, CA USA) was used 
during 4 minutes at room temperature and diluted 3:100. The final washing was performed 
with distillated water 2 x 5 minutes.  
Mayer’s hemalum solution (Millipore, Darmstadt, Germany) was used as counterstain 
for 10-20 seconds, depending of dye’s use. After coloration, slides were washed in running 
water for 5 minutes and the following step was sequential dehydration in 70% v/v ethanol 
for 2 x 4 minutes, 96% v/v ethanol for 2 x 4 minutes, 100% v/v ethanol for 2 x 4 minutes and 
xylene for 2 x 4 minutes. Mounting was performed with Microscopy Entellan (MERCK, 
Darmstadt, Germany). 
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4. EBV proteins expression analysis  
Epstein-Barr virus latent proteins were identified by immunohistochemistry (IHC) 
technique, which detects them in FFPE tissue, blocks using specific antibodies for each 
protein (table 7). IHC is a method for localizing specific antigens in FFPE tissues based on 
antigen–antibody interaction. The technique is widely used in dermatologic diagnostics and 
research, and its applications continue to be extended because of its ease of use, reliability, 
and versatility. In IHC an antigen–antibody construct is visualized through light microscopy 
by means of a colour signal.  
 
Protein Primary Antibody Dilution Incubation 
Positive expression in 
carcinoma cells 
LMP1 
NCL-EBV-CS1-4, 
Leica, Newcastle 
upon Tyne, UK 
1:100 3h, room temperature Cytoplasm 
LMP2A 
15F9, THERMO 
SCIENTIFIC, 
Fremont, USA 
1:250 Overnight, 4ºC Cytoplasm and membrane 
 
Tissue samples were dewaxed in xylene for 2 x 4 minutes. After dewaxing, slides were 
sequentially hydrated in 100% v/v ethanol for 2 x 4 minutes, 96% v/v ethanol for 2x4 
minutes; 70% v/v ethanol for 4 minutes and water for 5 minutes. Antigen retrieval was 
performed using a heat induced epitope retrieval method, where the slides were submersed 
a citrate-based antigen unmasking solution (VECTOR, Burlingame, CA USA) and heated 
in the microwave for 15 minutes at medium power. Slides were allowed to cold down to 
room temperature, rinsed in the unmasking solution for almost 20 minutes and then washed 
in Tris-buffer saline containing 0.02% Tween 20 (TBS-T), and the endogenous peroxidase 
was blocked with 3% hydrogen peroxide (H2O2) for 10 minutes. Subsequently, the slides 
were washed in TBS-T 2x 5 minutes, treated with UV-block solution from UltraVision Large 
Volume Detection System Anti-Polyvalent, HRP (THERMO SCIENTIFIC, Fremont, USA) 
for 10 minutes, to block nonspecific protein binding and incubated with the specific EBV 
latent protein antibodies (the specific conditions of each antibody are described in table 6). 
After being rinsed in TBS-T, Biotinylated Goat Anti-Polyvalent Antibody (THERMO 
SCIENTIFIC, Fremont, USA) was added and incubated in a humid chamber at room 
temperature for 10 minutes. The next step was washing with TBS-T 2 x 5 minutes following 
the addition of Streptavidin Peroxidase (THERMO SCIENTIFIC, Fremont, USA) with 
Table 7: Antibodies and conditions used for the detection of different EBV proteins 
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incubation for 10 minutes at room temperature. Detection of hybrids is achieved by 
enzymatic reaction using a specific substrate to peroxidase, 3, 3'-diaminobenzidine (DAB) 
ImmPACTTM DAB (VECTOR, Burlingame, CA USA) was used during 4 minutes at room 
temperature and diluted 3:100. The final washing was performed with water 2 x 5 minutes.  
Mayer’s hemalum solution (Millipore, Darmstadt, Germany) was used as counterstain 
for 10-30 seconds, depending of dye’s use. After coloration, slides were washed in running 
water for 5 minutes and the following step was sequential dehydration in 70% v/v ethanol 
for 4 minutes, 96% v/v ethanol for 2 x 4 minutes, 100% v/v ethanol for 2 x 4 minutes and 
xylene for 2 x 4 minutes. Mounting was performed with Microscopy Entellan (MERCK, 
Darmstadt, Germany). 
 
 
5. Quality control 
 
Positive and negative tissues controls were used in order to ensure the quality of the 
protocol. As a positive control for EBV proteins, PTLD FFPE tissue samples were used, 
once this malignancy expresses all EBV proteins. As for negative control, it was used GC 
or NPC FFPE tissue samples that lacked the specific antigen. 
 
6. Data analysis 
The clinicopathological characteristics of the tumour were compared to the expression 
of EBV latency proteins and consequently to the EBV latency pattern in GC and NPC 
pacients.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV. RESULTS
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1. EBER-ISH 
In all 9 cases of GC and 23 cases of NPC included in this study, a reconfirmation of 
the presence of EBV was preformed using the EBER-ISH technique. Of the 23 EBV positive 
NPC cases, a case has shown to have insufficient tumour tissue for performing the 
remaining tests and therefore, this case is going to be excluded from other tests, in this 
manner NPC cases were reduced to 22. In figure 14 it is represented the results of  EBER-
ISH in tumor samples. 
 
Figure 14: EBER-ISH Results A) GC EBV positive; B) NPC EBV positive; C) Negative control  
 
2. Protein expression 
 
2.1.  LMP1 
None of the cases of GC showed to be positive for LMP1. As for NPC, 21 (95.5%) 
of the examined cases have showed to be positive for LMP1 (Figure 15). In figure 16 it is 
represented LPM1 immunohistochemestry results in tumour samples. 
 
 
 
Negative
100%
GC
Positive
Negative
Positive
95,5%
Negative
4,5%
NPC
Positive
Negative
Figure 15: LMP1 results 
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Figure 16: IHC LMP1 results A) GC case negative for LMP1; B) NPC case positive for LMP1; C) NPC case 
negative for LMP1; D) Positive Control; E) Negative control 
 
2.2. LMP2A 
Of all cases of GC, only 4 proved to be positive for LMP2a. As for NPC, all 22 cases 
examined proved to be positive for LMP2a (Figure 17). In figure 18 it is represented LPM1 
immunohistochemestry results in tumour samples. 
 
 
 
 
 
Positive
44,4%Negative
55,6%
GC
Positive
Negative
Positive
100%
NPC
Positive
Negative
Figure 17: LMP2a results 
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Figure 18: IHC LMP2a results A) GC case positive for LMP2a; B) GC case negative for LMP2a; C) NPC case 
positive for LMP2a; D) Positive control; E) Negative control 
 
3. EBV latency 
Assuming that EBNA1 is expressed in all EBV associated tumours, it was given to 
each of the cases used in this study an EBV latency pattern based on the expression of 
LMP1 and LMP2a.   
 
3.1. NPC 
Table 8 describes the principal baseline characteristics of each NPC case used in 
this study, including sex, age, histological type and expressed proteins. The majority of 
cases, 21 (95.5%), had the expression of both LMP1 and LMP2a, which corresponds to a 
latency II pattern. Only 1 case (4.5%) expressed a distinct latency pattern similar to latency 
II, but without the expression of LMP1. This pattern is going to be referred as “latency II-
like”. 
 
3.2. EBVaGC 
Table 9 describes the principal baseline characteristics of each EBVaGC case used 
in this study, including sex, age, tumour location, histological type and expressed proteins. 
From all 9 cases of GC, 5 (55.6%) had no expression of LMP1 and LMP2a. In these, a 
latency I pattern is observed. The remaining 4 cases, had the expression of LMP2a, but not 
LMP1. These cases presented a “latency II-like” pattern. 
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ND – Not Determinated 
 
ID Gender Age 
Histological Type  
(WHO 2003) 
E
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L
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a
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y
 
P
a
tt
e
rn
 
1 F 44 
Undifferentiated  
non-keratinizing carcinoma 
+ + + II 
2 F 76 Undifferentiated  + + + II 
3 F 54 non-keratinizing carcinoma + + + II 
4 M 45 Undifferentiated  + + + II 
5 M 61 non-keratinizing carcinoma + + + II 
6 M 20 Undifferentiated  + + + II 
7 M 51 non-keratinizing carcinoma + + + II 
8 M 74 Undifferentiated  + + + II 
9 M 58 non-keratinizing carcinoma + + + II 
10 F 56 Undifferentiated  + + + II 
11 M 34 Undifferentiated  + + + II 
12 M 53 non-keratinizing carcinoma + + + II 
13 M 66 Undifferentiated  + + + II 
14 M 57 non-keratinizing carcinoma + + + II 
15 M 71 Undifferentiated  + + + II 
16 M 41 non-keratinizing carcinoma + + + II 
17 M 71 Undifferentiated  + + + II 
18 M 77 non-keratinizing carcinoma + + + II 
19 M 57 Undifferentiated  + + + II 
20 F 35 non-keratinizing carcinoma + + + II 
21 M 54 Undifferentiated  + + + II 
22 M 64 non-keratinizing carcinoma + - + II like 
ID gender Age Localization 
Histological Type 
(WHO 2010) 
E
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1 M 52 
Cardia, Fundus and 
Cardia/Fundus 
Lymphoepithelioma + - - I 
2 M 75 Corpus Tubular adenocarcinoma + - - I 
3 M 80 corpus/antrum Tubular adenocarcinoma + - - I 
4 F 68 Corpus Lymphoepithelioma + - - I 
5 M 80 Corpus Tubular adenocarcinoma + - - I 
6 M 82 
Cardia, Fundus and 
Cardia/Fundus 
Tubular adenocarcinoma + - - II like 
7 M 55 corpus/antrum Mixed adenocarcinoma + - - II like 
8 M 64 Corpus Tubular adenocarcinoma + - + II like 
9 F 66 
Antrum, Pylorus e 
Antrum/Pylorus 
Mixed adenocarcinoma + - + II like 
Table 9: Description of gastric cancer cases  
Table 8: Description of nasopharyngeal cancer cases  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V. DISCUSSION 
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EBV is a human cancer-associated virus that infects about 90% of the global 
population, without causing major symptoms in the majority of lifelong carriers [29, 192]. 
EBV is currently associated with many lymphoid and epithelial malignancies in both 
immunocompetent and immunocompromised individuals [52]. Even though the association 
of this virus with lymphoid malignancies is clear and relatively well understood, the same is 
not true for epithelial ones [52, 192].  Lately, there has been an increasing interest on the 
EBV-associated epithelial cancers that represent 80% of all EBV-associated malignancies 
[193]. Among these, NPC and EBVaGCs are the most common, with 78 000 and 84 000 
new cases, respectively, reported annually worldwide [193].  
According to literature, EBV infection can adopt four different patterns of latency, 
named type 0, I, II, and III [106]. In order correctly assign a latency pattern it must be taken 
into account the expression of at least four latent proteins, EBNA1, EBNA2, LMP1 and 
LMP2a [174, 175]. These specific latency EBV-transcription programmes have been 
associated with many human tumours and arise from specific stages in the EBV life cycle 
[176, 177, 194]. Nevertheless, there are several studies showing controversial information 
regarding the differential expression of EBV in some malignancies, hence we performed a 
retrospective study, in order to analyze the expression of EBV latency proteins and 
consequently the EBV latency pattern in NPC and EBVaGC. 
NPC pathogenesis is highly associated with EBV, with almost 100% of the undifferentiated 
types having evidence of EBV presence [195]. Literature suggests that NPC shows typically 
a Latency II pattern, were the expression of the EBERs and EBNA1 is accompanied by the 
expression of LMP1 and LMP2A/B [195], nevertheless some suggest that LMP1 expression 
is very variable, with only approximately 35% of cases being unequivocally positive for 
LMP1 [196]. Our results showed a higher percentage of LMP1 positivity (95.5%), which is 
in agreement with literature confirming the latency II pattern for the majority of our cases. 
Despite that, one case showed a pattern of viral protein expression similar to latency II 
presented in the other cases, but with no expression of LMP1 (latency II-like). Failure to 
detect the LMP1 in one case may reflect biological heterogeneity or may be due to 
limitations of the paraffin-embedded IHC method as has been reported by others [197, 198]. 
Some researchers showed that the invasion and metastasis of NPC is promoted by LMP1, 
and a few studies have also shown a worse prognosis and survival [199] [200, 201] even 
though others studies argued that LMP1 is not associated with NPC prognosis [202, 203]. 
Through our results, it was not possible to draw any conclusions regarding the role of LMP1 
on the prognosis in NPC cases, once the only case that had no expression of LMP1 had 
very similar clinicopathological characteristics to many of the ones that expressed LMP1. 
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EBVaGC is a “new” entity that has been described as a distinct subtype that 
accounts for nearly 10% of gastric carcinomas with specific clinicopathological features, 
including predominance among males and a proximal location in the stomach.  [204]. Since 
EBVAGC has been subject to controversial information regarding EBV association and 
protein expression, we have performed a systematic review on the expression of different 
latent EBV proteins described in literature. The literature review showed that, EBNA1 is 
expressed in 98%, while LMP2a is only expressed in 52% of cases, while there was no 
evidence of EBNA2 and LMP1 expression (Table 10). Hence, this information results in 
three different types of latency patterns (Table 11). Interestingly, the majority of the cases 
showed a pattern of viral protein expression, where only EBNA1 and LMP2a were 
expressed. This type of latency is a midterm between the latency I and latency II patterns, 
described as Latency II-like pattern. The second most frequent latency, present in 46% of 
cases was latency I, which is the type of latency manly attributed to EBVaCGs. 
Nevertheless, we have also observed one case showing a latency 0 pattern that is usually 
only seen in memory B cells.  
Table 10: Frequency of EBV latent proteins observed in different studies 
Study n 
EBNA1 
n (%) 
EBNA2 
n (%) 
LMP1 
n (%) 
LMP2A  
n (%) 
LMP2B 
n (%) 
Cheng N, et al. 2014 [189] 7 7 (100) 0 (0) 0 (0) 5 (71.4) ---- 
Lee JM. et al. 2011 [205] 4 4 (100) 0 (0) 0 (0) 1 (25.0) ---- 
Chen J. et al. 2011 [185] 8 7 (87.5) 0 (0) 0 (0) 5 (62.5) ---- 
Luo B, et al. 2005 [188] 11 11 (100) 0 (0) 0 (0) 4 (36.4) 0 (0) 
Hoshikawa Y, et al. 2002 [186] 3 3 (100) 0 (0) 0 (0) 2 (66.7) ---- 
zur Hausen A, et al. 2000 [187] 10 10 (100) 0 (0) 0 (0) 6 (60.0) ---- 
Sugiura M, et al. 1996 [206] 7 7 (100) 0 (0) 0 (0) 3 (42.9) 0 (0) 
TOTAL n(%) 50 49/50 (98.0) 0/50 (0) 0/50 (0) 26/50 (52.0) 0/19 (0) 
 
 
Table 11: Frequency of EBV latency patterns observed in different studies 
Study n 
Lat 0  
n(%) 
Lat I  
n(%) 
Lat II  
n(%) 
Lat III 
n(%) 
Lat  “II-like” 
n(%) 
Cheng N, et al. 2014 [189] 7 - 2 (28.6) - - 5 (71.4) 
Lee JM. et al. 2011 [205] 4 - 3 (75.0) - - 1 (25.0) 
Chen J. et al. 2011 [185] 8 1 (12.5) 2 (25.0) - - 5 (62.5) 
Luo B, et al. 2005 [188] 11 - 7 (63.6) - - 4 (36.4) 
Hoshikawa Y, et al. 2002 [186] 3 - 1 (33.3) - - 2 (66.7) 
zur Hausen A, et al. 2000 [187] 10 - 4 (40.0) - - 6 (60.0) 
Sugiura M, et al. 1996 [206] 7 - 4 (57.1%) - - 3 (42.9%) 
TOTAL n(%) 50 1/50 (2.0) 23/50 (46.0) 0/50 (0) 0/50 (0) 26/50 (52.0) 
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In our study, the results were congruent to those described from this literature 
review, since both of the most frequent latency patterns were also observed in our study. 
The only difference was that latency I, was the most frequent with 55.6% of cases, while 
latency II-like was observed in 44.4% of the cases. It is suggested by literature that, the lack 
of LMP1 expression in EBVaGC, indicates that LMP1 may not be necessary for maintaining 
the tumour malignant state, but it might participate in an earlier stage of the tumour 
development, and is down-regulated afterwards  [206]. Alternatively, the lack of LMP1 may 
result of a clonal selection of LMP1-negative tumour cells by immunological pressure, once 
EBV-specific cytotoxic T cells are potentially directed against the viral latent proteins other 
than EBNA1 [206]. Recently, it was also demonstrated that LMP2A up-regulates surviving 
gene expression through the NF-kB pathway and that it up-regulates cellular DNA 
methyltransferase 1 through the phosphorylation of STAT3, causing promoter 
hypermethylation of a tumour suppressor gene, PTEN, in EBVaGC [185]. Since LMP2A has 
demonstrated to play important roles in the oncogenic processes of EBVaGC, and it is 
expressed in about half of the cases, it is crucial to not be restricted to three types of latency 
patterns that are described and accepted by literature, and thereby new ones, with different 
tyes of protein expression, should be taken into consideration.  
Even though our results are important and this is the first study to describe latency 
patterns in our population, it would be important to complement this work with some extra 
information. For example, compare GC llymphoepithelioma with NPC undifferentiated non-
keratinizing carcinoma, once they have similar histology, but it seems that they have 
different latency patter, for this it would be necessary to increase the number of cases of 
GC.  It would be also important to complement our results with information from other 
proteins, such as EBNA1, that in this study is assumed to be expressed in very tumour, but 
it should be done in order to eliminate possible doubts of the existence of latency 0; EBNA2; 
and finally BARF1, once it is suggested by literature that it might act as a viral oncogene in 
the development of EBVaGC [187].  
It is very important correctly identify all latency patterns and which carcinogenic 
processes are taking place in each of them, because once we know it, it is much easier to 
have an accurate prognosis and by consequence a proper treatment for each individual. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
VI. CONCLUSION
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EBV infection can adopt different patterns of latency, and these have a close 
correlation with the different types of EBV associated diseases. With this study it was possible 
to confirm that in our population, NPC is characterized by a latency II pattern, while EBVaGC 
shows a latency I pattern.  We were also able to identify a novel, and yet not accepted, 
latency pattern associated mainly associated with EBVaGC, but also described in one case 
of NPC. We described that latency pattern as latency II-like, and it is characterized by the 
expression of EBNA1 and LMP2a.  
This is the first study regarding latency patterns of NPC and EBVaGC in Portugal 
and further studies are required to confirm these evidences, especially with more cases and 
ideally from different regions of Portugal. It also important to increase the panel of proteins 
studied so we can correctly describe the different latency patterns, and in order to better 
understand the role of each protein in tumour carcinogenesis, functional assays would also 
be important. 
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